Figure 3
From: Serelaxin improves cardiac and renal function in DOCA-salt hypertensive rats

Serelaxin decreased kidney fibrosis of DOCA-salt rats. (a) DOCA increased periglomerular and tubulointerstitial fibrosis, as determined by Picrosirius Red staining, and treatment with serelaxin markedly decreased the periglomerular and tubulointerstitial fibrosis. (b) Second Harmonic Generation (SHG) Microscopy showed DOCA induced a marked increase in tubulointerstitial fibrosis and treatment with serelaxin markedly decreased the fibrosis. Quantitative real-time PCR (qRT-PCR) analysis showed treatment with serelaxin prevented the increases in the (c) profibrotic factor TGF-β, (d) collagen1A and (e) collagen 3 A gene expression in the kidney. Results are expressed as means ± SEM (n = 6 rats). Statistical analysis was performed with one-way ANOVA.